Connect with us

Wellness

Contrast-enhanced ultrasound, perfluorobutane diagnoses high-risk hepatocellular carcinoma

Leesburg, VA, November 16, 2022—According to an accepted manuscript published in ARRS’ American Journal of Roentgenology (AJR), diagnostic performance…

Published

on

This article was originally published by BioEngineering

Leesburg, VA, November 16, 2022—According to an accepted manuscript published in ARRS’ American Journal of Roentgenology (AJR), diagnostic performance of LR-5 for hepatocellular carcinoma (HCC) diagnosis was not significantly different between modified contrast-enhanced ultrasound (CEUS) using perfluorobutane and CT/MRI LI-RADS version 2018.

71-year-old woman at high-risk for HCC due to chronic hepatitis B. Patient underwent CEUS using perfluorobutane.

Credit: ARRS/AJR

Leesburg, VA, November 16, 2022—According to an accepted manuscript published in ARRS’ American Journal of Roentgenology (AJR), diagnostic performance of LR-5 for hepatocellular carcinoma (HCC) diagnosis was not significantly different between modified contrast-enhanced ultrasound (CEUS) using perfluorobutane and CT/MRI LI-RADS version 2018.

 

“The findings support the application of modified CEUS criteria using perfluorobutane for diagnosing HCC in high-risk patients,” wrote Jianhua Zhou, MD, PhD, of Sun Yat-Sen University Cancer Center’s State Key Laboratory of Oncology in Guangzhou, South China.

 

In this AJR accepted manuscript, 171 patients (140 men, 31 women; mean age, 54 years) at high risk for HCC with a pathologically confirmed liver observation were evaluated by both CEUS using perfluorobutane and contrast-enhanced CT or MRI, between March 2020 and May 2021. A matching algorithm was used to select 2 patients with HCC for each patient with a non-HCC lesion. Two readers evaluated observations using proposed modifications to CEUS LI-RADS version 2017 that classify certain observations as LR-5—rather than LR-4 or LR-M, based on presence of defect post-perfluorobutane administration.

 

Ultimately, modified CEUS criteria using perfluorobutane and CT/MRI LI-RADS v2018 showed no significant difference in sensitivity (92.1% vs. 89.5%), specificity (87.9% vs. 84.2%), or accuracy (90.6% vs. 87.7%) of LR-5 for HCC. All observations assigned LR-4 (n=5) or LR-M (n=6) by CT/MRI LI-RADS v2018 but LR-5 by modified CEUS were HCC.

 

“Modified CEUS criteria performed similarly as CT/MRI LI-RADS v2018 and additional HCCs in a subset of observations assigned LR-4 or LR-M by CT/MRI LIRADS v2018,” the authors of this AJR accepted manuscript reiterated.

 

An electronic supplement to this AJR accepted manuscript is available here.


North America’s first radiological society, the American Roentgen Ray Society (ARRS) remains dedicated to the advancement of medicine through the profession of medical imaging and its allied sciences. An international forum for progress in radiology since the discovery of the x-ray, ARRS maintains its mission of improving health through a community committed to advancing knowledge and skills with the world’s longest continuously published radiology journal—American Journal of Roentgenology—the ARRS Annual Meeting, InPractice magazine, topical symposia, myriad multimedia educational materials, as well as awarding scholarships via The Roentgen Fund®.

 

MEDIA CONTACT:

Logan K. Young, PIO

44211 Slatestone Court

Leesburg, VA 20176

703-858-4332

lyoung@arrs.org





Wellness

Lion’s Mane Mushroom: History, Benefits, and Adaptogen Properties

Explore the intriguing world of Lion’s Mane Mushroom in our comprehensive guide. Dive into its unique properties, historical significance, and myriad health…

Continue Reading
Medtech

AI can already diagnose depression better than a doctor and tell you which treatment is best

Artificial intelligence (AI) shows great promise in revolutionizing the diagnosis and treatment of depression, offering more accurate diagnoses and predicting…

Continue Reading
Wellness

Reasons You should Get this: Neptune Wellness Solutions Inc (NASDAQ:NEPT), WeTrade Group Inc. (NASDAQ:WETG)

NEPT has seen its SMA50 which is now -9.28%. In looking the SMA 200 we see that the stock has seen a -92.25%. WETG has seen its SMA50 which is …
The…

Continue Reading

Trending